Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 17Sarcoma 13Lymphoid 11Gynecologic 9CNS 6Tumor-Agnostic 4Other hematologic neoplasm 4Breast 4Head & Neck 3Gastrointestinal 3Dermatologic 3Thoracic 2Plasma cell 1Other solid neoplasm 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × temsirolimus × Thoracic × Clear all
NCT01827267 2018-07-03

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Puma Biotechnology, Inc.

Phase 2 Completed
62 enrolled 12 charts
Thoracic

Lung Neoplasms

NCT00921310 2016-12-13

Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

Washington University School of Medicine

Phase 1/2 Terminated
12 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡